Relevant bibliographies by topics / Antithrombotic strategies

Academic literature on the topic 'Antithrombotic strategies'

Author: Grafiati
Published: 10 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Antithrombotic strategies.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Antithrombotic strategies"

1

Guedeney, Paul, and Jean-Philippe Collet. "Antithrombotic strategies following TAVR." Sang thrombose vaisseaux 33, no. 1 (February 2021): 19–24. http://dx.doi.org/10.1684/stv.2021.1155.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Hasan, Md Nazmul, Md Abu Siddique, Sajal Krishna Banerjee, Syed Ali Ahsan, AKM Fazlur Rahman, Choudhury Meshkat Ahmed, Mohammad Faisal Ibn Kabir, and Md Harisul Hoque. "Antithrombotic Strategies in Perioperative Period." University Heart Journal 9, no. 1 (July 14, 2014): 47–51. http://dx.doi.org/10.3329/uhj.v9i1.19511.

Full text
Abstract:
Antithrombotic therapy (Warfarin, Aspirin,Clopidogrel etc.) are routinely used in prevention and treatment of various cardiovascular diseases. In patients who are having a surgical or other invasive procedure, interruption of antithrombotic therapy is typically required to minimize the risk for perioperative bleeding. It involves balancing the risk of periprocedural bleeding with continued treatment against the thrombotic risk with suspension of treatment and use of bridging anticoagulation therapy. The need for bridging is driven by patients’ estimated risk for thromboembolism and the bleeding risk of invasive procedure. Treatment with subcutaneous low-molecular- weight heparin or intravenous unfractionated heparin at a therapeutic dose before and after the procedure recommended as bridging anticoagulation therapy. DOI: http://dx.doi.org/10.3329/uhj.v9i1.19511 University Heart Journal Vol. 9, No. 1, January 2013; 47-51
APA, Harvard, Vancouver, ISO, and other styles
3

Gremmel, Thomas, and Kurt Huber. "Antithrombotic treatment strategies after PCI." Lancet 395, no. 10227 (March 2020): 865. http://dx.doi.org/10.1016/s0140-6736(20)30028-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

De Caterina, Raffaele, and Ugo Limbruno. "Antithrombotic treatment strategies after PCI." Lancet 395, no. 10227 (March 2020): 865. http://dx.doi.org/10.1016/s0140-6736(20)30029-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Jeong, Young-Hoon, Yong-Lee Kim, Udaya Tantry, and Paul A. Gurbel. "Antithrombotic treatment strategies after PCI." Lancet 395, no. 10227 (March 2020): 866–67. http://dx.doi.org/10.1016/s0140-6736(20)30030-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Romiti, Giulio Francesco, Stefania Basili, and Marco Proietti. "Antithrombotic treatment strategies after PCI." Lancet 395, no. 10227 (March 2020): 866. http://dx.doi.org/10.1016/s0140-6736(20)30031-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Auer, Johann, Robert Berent, and Franz Gurtner. "Antithrombotic treatment strategies after PCI." Lancet 395, no. 10227 (March 2020): 865–66. http://dx.doi.org/10.1016/s0140-6736(20)30032-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Channon, Keith M., and Brian H. Annex. "Antithrombotic strategies in gene therapy." Current Cardiology Reports 2, no. 1 (January 2000): 34–38. http://dx.doi.org/10.1007/s11886-000-0023-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Gurbel, Paul A., Palak Shah, Shashank Desai, and Udaya S. Tantry. "Antithrombotic Strategies and Device Thrombosis." Cardiology Clinics 36, no. 4 (November 2018): 541–50. http://dx.doi.org/10.1016/j.ccl.2018.06.008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Shishehbor, Mehdi H., and Barry T. Katzen. "Antithrombotic Strategies in Endovascular Interventions." Interventional Cardiology Clinics 2, no. 4 (October 2013): 627–33. http://dx.doi.org/10.1016/j.iccl.2013.06.005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Antithrombotic strategies"

1

Bellandi, Benedetta. "Pharmacodynamic of antithrombotic therapies in high cardiovascular risk patients." Doctoral thesis, 2018. http://hdl.handle.net/2158/1129305.

Full text
Abstract:
This thesis addresses different aspects of antithrombotic strategies in patients with acute coronary syndrome, mainly in ST elevation acute myocardial infarction (STEMI) patients treated with percutaneous coronary intervention (PCI), regarding their efficacy and safety during the acute phase as well as their appropriateness and impact on long-term outcomes.
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Antithrombotic strategies"

1

Askari, Arman. Management strategies in antithrombotic therapy. Chichester: John Wiley and Sons, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Askari, Arman, Michael Lincoff, and Adrian Messerli. Management Strategies in Antithrombotic Therapy. Wiley & Sons, Incorporated, John, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Askari, Arman, Michael Lincoff, and Adrian Messerli. Management Strategies in Antithrombotic Therapy. Wiley & Sons, Limited, John, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Management Strategies in Antithrombotic Therapy. Wiley-Interscience, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

McDonald, Vickie, and Marie Scully. Anticoagulants and antithrombotics in critical illness. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199600830.003.0051.

Full text
Abstract:
Coagulation is best thought of using the cell-based model of coagulation. Patients commenced on heparin therapy should have their platelet count monitored early because of the risk of heparin-induced thrombocytopenia, which can occur on any type or dose of heparin. Emergency reversal of warfarin should be with prothrombin complex concentrate (containing factors II, VII, IX, and X) and not fresh frozen plasma. New oral anticoagulants have the advantage of predictable pharmacokinetics and do not require routine monitoring, but optimal reversal strategies for these agents are not clear. Thrombolytic agents lead to variable degrees of systemic lysis, which may cause haemorrhage, including intracerebral haemorrhage
APA, Harvard, Vancouver, ISO, and other styles
6

Mannucci, Pier Mannuccio. Bleeding and haemostasis disorders. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199687039.003.0070.

Full text
Abstract:
The main cause of haemostasis defects and related bleeding complications in patients with acute coronary syndromes admitted to the intensive cardiac care unit is the use of multiple antithrombotic drugs, alone or concomitantly with invasive procedures such as percutaneous coronary intervention with stent deployment and coronary artery bypass surgery. These drugs, that act upon several components of haemostasis (platelet function, coagulation, fibrinolysis), are associated with bleeding complications, particularly in elderly patients (more so in women than in men), those who are underweight, and those with comorbid conditions such as renal and liver insufficiency and diabetes. The identification of patients at higher risk of bleeding is the most important preventive strategy. Red cell and platelet transfusions, which may become necessary in patients with severe bleeding, should be used with caution, because transfused patients with acute coronary syndrome have a high rate of adverse outcomes (death, myocardial infarction, and stroke). To reduce the need of transfusion, haemostatic agents that decrease blood loss and transfusion requirements (antifibrinolytic amino acids, plasmatic prothrombin complex concentrates, recombinant factor VIIa) may be considered. However, the efficacy of these agents in the control of bleeding complications in acute coronary syndrome is not unequivocally established, and there is concern for an increased risk of re-thrombosis. A low platelet count is another cause of bleeding in the intensive cardiac care unit. The main aetiologies are drugs (unfractionated heparin and glycoprotein IIb/IIIa inhibitors), thrombotic microangiopathies, such as thrombotic thrombocytopenic purpura, and disseminated intravascular coagulation, that are often paradoxically associated with thrombotic manifestations. In conclusion, evidence-based recommendations for the management of bleeding in patients admitted to the intensive cardiac care unit are lacking. Accurate assessments of the risk of bleeding in the individual and prevention measures are the most valid strategies.
APA, Harvard, Vancouver, ISO, and other styles
7

Mannucci, Pier Mannuccio. Bleeding and haemostasis disorders. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199687039.003.0070_update_001.

Full text
Abstract:
The main cause of haemostasis defects and related bleeding complications in patients with acute coronary syndromes admitted to the intensive cardiac care unit is the use of multiple antithrombotic drugs, alone or concomitantly with invasive procedures such as percutaneous coronary intervention with stent deployment and coronary artery bypass surgery. These drugs, that act upon several components of haemostasis (platelet function, coagulation, fibrinolysis), are associated with bleeding complications, particularly in elderly patients (more so in women than in men), those who are underweight, and those with comorbid conditions such as renal and liver insufficiency and diabetes. The identification of patients at higher risk of bleeding is the most important preventive strategy. Red cell and platelet transfusions, which may become necessary in patients with severe bleeding, should be used with caution, because transfused patients with acute coronary syndrome have a high rate of adverse outcomes (death, myocardial infarction, and stroke). To reduce the need of transfusion, haemostatic agents that decrease blood loss and transfusion requirements (antifibrinolytic amino acids, plasmatic prothrombin complex concentrates, recombinant factor VIIa) may be considered. However, the efficacy of these agents in the control of bleeding complications in acute coronary syndrome is not unequivocally established, and there is concern for an increased risk of re-thrombosis. A low platelet count is another cause of bleeding in the intensive cardiac care unit. The main aetiologies are drugs (unfractionated heparin and glycoprotein IIb/IIIa inhibitors), thrombotic microangiopathies, such as thrombotic thrombocytopenic purpura, and disseminated intravascular coagulation, that are often paradoxically associated with thrombotic manifestations. In conclusion, evidence-based recommendations for the management of bleeding in patients admitted to the intensive cardiac care unit are lacking. Accurate assessments of the risk of bleeding in the individual and prevention measures are the most valid strategies.
APA, Harvard, Vancouver, ISO, and other styles
8

Mannucci, Pier Mannuccio. Bleeding and haemostasis disorders. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199687039.003.0070_update_002.

Full text
Abstract:
The main cause of haemostasis defects and related bleeding complications in patients with acute coronary syndromes admitted to the intensive cardiac care unit is the use of multiple antithrombotic drugs, alone or concomitantly with invasive procedures such as percutaneous coronary intervention with stent deployment and coronary artery bypass surgery. These drugs, that act upon several components of haemostasis (platelet function, coagulation, fibrinolysis), are associated with bleeding complications, particularly in elderly patients (more so in women than in men), those who are underweight, and those with comorbid conditions such as renal and liver insufficiency and diabetes. The identification of patients at higher risk of bleeding is the most important preventive strategy. Red cell and platelet transfusions, which may become necessary in patients with severe bleeding, should be used with caution, because transfused patients with acute coronary syndrome have a high rate of adverse outcomes (death, myocardial infarction, and stroke). To reduce the need of transfusion, haemostatic agents that decrease blood loss and transfusion requirements (antifibrinolytic amino acids, plasmatic prothrombin complex concentrates, recombinant factor VIIa) may be considered. However, the efficacy of these agents in the control of bleeding complications in acute coronary syndrome is not unequivocally established, and there is concern for an increased risk of re-thrombosis. A low platelet count is another cause of bleeding in the intensive cardiac care unit. The main aetiologies are drug usage (unfractionated heparin and glycoprotein IIb/IIIa inhibitors), such thrombotic microangiopathies as thrombotic thrombocytopenic purpura and disseminated intravascular coagulation, that are often paradoxically associated with thrombotic manifestations. In conclusion, evidence-based recommendations for the management of bleeding in patients admitted to the intensive cardiac care unit are lacking. Accurate assessments of the risk of bleeding in the individual and prevention measures are the most valid strategies.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Antithrombotic strategies"

1

Bitar, Jamil, Salim Dabaghi, Selim Sekili, and Neil S. Kleiman. "Novel Antithrombotic Strategies." In Unstable Coronary Artery Syndromes Pathophysiology, Diagnosis and Treatment, 241–75. Boston, MA: Springer US, 1998. http://dx.doi.org/10.1007/978-1-4615-5715-9_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Leblond, L., and P. D. Winocour. "The Coagulation Pathway and Antithrombotic Strategies." In Antithrombotics, 1–39. Berlin, Heidelberg: Springer Berlin Heidelberg, 1999. http://dx.doi.org/10.1007/978-3-642-59942-2_1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Shishehbor, Mehdi H. "Antithrombotic Strategies in Endovascular Interventions." In Interventional Cardiology, 754–58. Chichester, UK: John Wiley & Sons, Ltd, 2016. http://dx.doi.org/10.1002/9781118983652.ch82.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Schoos, Mikkel Malby, Davide Capodanno, and George D. Dangas. "Antithrombotic Strategies in Valvular and Structural Heart Disease Interventions." In Interventional Cardiology, 507–16. Chichester, UK: John Wiley & Sons, Ltd, 2016. http://dx.doi.org/10.1002/9781118983652.ch53.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Rao, Sunil V., and E. Magnus Ohman. "Antithrombotic Strategies in Patients Undergoing Elective Percutaneous Coronary Intervention." In Therapeutic Advances in Thrombosis, 236–45. Oxford, UK: Blackwell Publishing Ltd., 2012. http://dx.doi.org/10.1002/9781118410875.ch16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Deckmyn, H., P. Gresele, J. Arnout, and J. Vermylen. "Manipulation of Pro- and Antiaggregating Prostaglandins: New Antithrombotic Strategies." In Drugs Affecting Leukotrienes and Other Eicosanoid Pathways, 141–47. Boston, MA: Springer US, 1985. http://dx.doi.org/10.1007/978-1-4684-7841-9_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Margaglione, M., E. Grandone, F. P. Mancini, and G. Di Minno. "Drugs affecting plasma fibrinogen levels. Implications for new antithrombotic strategies." In Progress in Drug Research/Fortschritte der Arzneimittelforschung/Progrès des recherches pharmaceutiques, 169–81. Basel: Birkhäuser Basel, 1996. http://dx.doi.org/10.1007/978-3-0348-8996-4_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Wali, Eisha, and Sandeep Nathan. "Newest Antithrombotic Agents: Uses, Challenges, and Reversal Strategies for Surgical Procedures." In Difficult Decisions in Surgery: An Evidence-Based Approach, 481–97. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-04146-5_33.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Mejevoi, Nicolai, Catalin Boiangiu, and Marc Cohen. "Antiplatelet therapy versus other antithrombotic strategies." In Platelets in Hematologic and Cardiovascular Disorders, 367–85. Cambridge University Press, 2001. http://dx.doi.org/10.1017/cbo9780511545276.023.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Kristensen, Steen D., Kurt Huber, and Michael Maeng. "Risk reduction strategies: perioperative management in patients on antithrombotic therapy." In ESC CardioMed, edited by Steen Kristensen, 2657–59. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198784906.003.0638.

Full text
Abstract:
The choice of disruption or continuation of antithrombotic drugs prior to non-cardiac surgery is a challenging issue for surgeons and cardiologists. The type of surgery, cardiac diagnosis, and indication for antithrombotic therapy should be evaluated and discussed. This chapter provides some guidance for clinicians on how to balance bleeding and perioperative thrombotic complications.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Antithrombotic strategies' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography